Ivermectin Shortage: What Providers and Prescribers Need to Know in 2026

Ivermectin remains a cornerstone treatment for several parasitic infections — strongyloidiasis, onchocerciasis, scabies (off-label), and others — but your patients may encounter significant pharmacy-level barriers when attempting to fill their prescriptions. This guide provides clinically actionable information on the current supply environment, evidence-based alternatives by indication, and communication strategies to support your patients.

Current Supply Status for Clinicians (2026)

Ivermectin tablets (3 mg) are not on the FDA's official Drug Shortage Database as of early 2026, indicating no documented nationwide manufacturing shortage. However, localized distribution gaps remain common. Patients in rural areas, regions with active scabies outbreaks, and smaller pharmacy markets frequently report difficulty locating adequate stock. The FDA shortage database does not capture these localized distribution failures.

The American Society of Health-System Pharmacists (ASHP) maintains a separate current shortages list that may capture issues the FDA database does not. Checking both databases before assuming availability is advisable when prescribing for high-acuity indications.

Clinical Context: Why Ivermectin Availability Remains Variable

The 2021-2022 pandemic-driven demand surge — driven by off-label COVID-19 use despite no evidence of efficacy — exposed structural vulnerabilities in ivermectin's supply chain. Generic drug manufacturing operates on thin margins with shared production infrastructure. A surge in demand cannot be rapidly accommodated, and the downstream effects on distributor inventory management have not fully resolved.

Additionally, the expanding OTC access landscape — with four states (Tennessee, Arkansas, Idaho, Louisiana) having enacted OTC dispensing laws as of 2025 — is reshaping how pharmacies in those states stock and categorize the product, introducing further variability.

Evidence-Based Alternatives by Indication

Strongyloidiasis (Intestinal Strongyloides stercoralis)

Ivermectin remains the preferred agent for its superior cure rates (90%+ with a single 200 mcg/kg dose). In unavailability situations:

• Albendazole 400 mg BID x 7 days: Cure rates of 38-95% (heterogeneous data); significantly inferior to ivermectin for disseminated or hyperinfection syndrome. Not appropriate as the sole agent in immunocompromised patients with disseminated disease.
• Thiabendazole: Historical comparator, largely abandoned due to poor tolerability. Use only if no other option exists.

Clinical note: In hyperinfection or disseminated strongyloidiasis — which carries mortality rates of 60-87% without treatment — escalating urgency to locate ivermectin is essential. Consider contacting compounding pharmacies and infectious disease consultants when commercial supply is unavailable.

Onchocerciasis (River Blindness)

• Moxidectin (Moxidectin): FDA-approved for onchocerciasis in adults and adolescents ≥12 years (2018). Same avermectin class as ivermectin. A single 8 mg oral dose; may provide longer suppression of microfilaridermia than ivermectin's standard dosing.
• Doxycycline: Targets Wolbachia endosymbionts; 100 mg BID x 6 weeks reduces embryogenesis and adult worm fertility. Not microfilaricidal per se but adjunctive. Avoid in children <8 years and pregnancy.

Scabies (Off-Label Ivermectin Use)

• Permethrin 5% cream: First-line topical; applied from neck to toes, 8-14 hours, repeated in 1-2 weeks. Effective for typical scabies in immunocompetent patients.
• Crotamiton 10% cream (Eurax): Lower efficacy but an option for patients who cannot tolerate permethrin.

Clinical note on crusted scabies: Crusted (Norwegian) scabies in immunocompromised patients (HIV, transplant recipients, HTLV-1) requires combination oral ivermectin plus topical therapy. Topical permethrin alone is insufficient. Contact your infectious disease colleague and escalate urgently if ivermectin is unavailable.

Compounding as a Bridge Option

If commercially manufactured ivermectin tablets are unavailable in your market, licensed compounding pharmacies may be able to prepare the medication from bulk API. This requires a 503A compliant prescription and a compounding pharmacy relationship. Compounded ivermectin is not FDA-approved as a finished product but may be permissible under state law for specific patients when the commercial product is genuinely unavailable.

Patient Communication Strategy

When prescribing ivermectin, proactively tell patients that they may need to call more than one pharmacy. Direct them to check independent pharmacies, warehouse clubs, and grocery store pharmacies in addition to major chains. Consider directing patients to medfinder.com/providers — a service that calls pharmacies on patients' behalf to locate available stock, removing that burden from both the patient and your office.

Providing patients with a backup plan at the time of prescribing — including the option of medfinder — reduces callbacks to your office and improves treatment adherence for conditions that require urgent therapy.

Special Populations to Prioritize

• Immunocompromised patients with strongyloidiasis: Risk of hyperinfection is high; delay in treatment can be fatal. Escalate urgently.
• Patients with crusted scabies: Oral ivermectin is essential; topical therapy alone is inadequate.
• Patients being initiated on corticosteroids or immunosuppression: Undetected strongyloidiasis can convert to hyperinfection with immunosuppression. Screening before initiation is standard of care; ensure treatment is accessible before starting immunosuppressive therapy.